Competition & Peer Data API & CSV Delivery

Aslan Pharmaceuticals Limited's Competitiveness

Name: Aslan Pharmaceuticals Limited Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Aslan Pharmaceuticals Limited (ASLN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2023

Competitors Tracked

Publicly traded peers

Peer Group Market Share

100.00 %

Share of combined sales, Q4 2023

Revenue Growth Y/Y

Q4 2023

Net Margin

-368.50 %

Q4 2023

Key Findings: Aslan Pharmaceuticals Limited vs Its Competitors

TTM: Trailing 12-month revenue of 12M vs -M combined for tracked competitors (100.0% combined share).
Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Peer revenue share: Aslan Pharmaceuticals Limited accounted for 100.0% of combined revenue among its tracked peer group.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

ASLN Sales vs. its Competitors, Q4 2023

Aslan Pharmaceuticals Limited generated 100.00 % of the combined sales of its peer group.

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/ASLN/competitors                    

                        https://api.csimarket.com/api/v1/companies/ASLN/relationships                    

                        https://api.csimarket.com/api/v1/companies/ASLN/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Aslan Pharmaceuticals Limited's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Aslan Pharmaceuticals Limited	-	-	-	-
High-Confidence Competitors (1)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

ASLN Stock Performance relative to its Competitors

ASLN Competitors (weighted) Percent change over the selected range

Aslan Pharmaceuticals Limited's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(0 of 1)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Aslan Pharmaceuticals Limited	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (1)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Aslan Pharmaceuticals Limited's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

ASLN Stock Performance relative to High-Confidence Competitors

ASLN High-Confidence Competitors (equal-weighted, 1) Percent change over the selected range

Aslan Pharmaceuticals Limited's Comment on Competition and Industry Peers

The company faces competition from existing and potential therapies. It co-owns certain intellectual property with CSL Limited, and these co-owners may license rights to third parties, including competitors, who could develop competing products and technologies. The company may require cooperation from co-owners to license or enforce patents, which may not be granted, potentially impacting its competitive position. Additionally, the company relies on trade secret protection and confidentiality agreements to maintain its competitive advantage.

Aslan Pharmaceuticals Limited's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
CSL Limited	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Aslan Pharmaceuticals Limited's named competitors require a Commercial License.